CEACAM5 and colorectal carcinoma: The first CAR-T clinical trial for CRC, which started in 2014, studied the safety and efficacy of second-generation CEA-CAR-T cells in patients with CRC, and also included lung, gastric, breast and pancreatic cancer patients (NCT02349724).